Is Teva (TEVA +1.21%) genuinely concerned about Biogen's (BIIB +0.48%) BG-12's safety, or is it more concerned about the oral MS drug's impact to its own Copaxone sales? Motley Fool health-care analyst David Williamson dives into the surprise plea to the FDA and what it means for investors.
Is Teva Just Looking Out for Itself
By Dave Williamson – Jan 11, 2013 at 7:08PM
NYSE: TEVA
Teva Pharmaceutical Industries
Market Cap
$28B
Today's Change
(1.21%) $0.29
Current Price
$24.26
Price as of November 10, 2025 at 4:00 PM ET
It sent the FDA a citizens' petition regarding a pending competitor.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid